Thomas Kindt, chief scientific officer of InNexus, said: “Under the existing collaborative agreement, the NCI is expected to continue to evaluate our proprietary technology as applied to certain immunotoxins currently in development at the NCI.
“Under the amended agreement we will receive additional immunotoxins for modification in our own facilities to enhance activity and function and the NCI will evaluate the modified immunotoxins against unmodified product.”
Jeff Morhet, CEO of InNexus, said: “Work will now be conducted in both houses, and our R&D effort is expanded. Our scientists are excited to apply InNexus technology to the NCI’s anti-cancer compounds (immunotoxins) in our laboratories.
“These modified products are expected to be tested by the NCI for activity against tumor cells in comparison with the unmodified compounds giving independent evaluation of our new technology.”